Michael G. King, Jr.

Michael G. King, Jr.

EVP, Chief Financial OfficeratSAB Biotherapeutics· In proxies 2022–2023

Pay in FY2023SAB Biotherapeutics stock +16.5% the same year

Michael G. King, Jr. was paid $722.0K in FY2023 (Dec). SAB Biotherapeutics stock rose 16.5% that year.

Pay$100 in the stock at the end of FY21 → $9
Pay is from the Summary Compensation Table of each SAB Biotherapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. SAB BiotherapeuticsPublic company · 4 yr
    • EVP, Chief Financial Officer2022 – Present · 4 yrStock in role -96%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?